Active Biotech Ab

Trikonex Ab

Aktiebolaget Leo

Transientic Interactions Ab

Tomas Fex

Gunnar Hedlund

Anders K Bjork

Stig Jonsson

Anders Bj&ouml;rk

Stig J&ouml;nsson

Aina L Abramo

Erik G Christensson

Knut G Olsson

Per Axel Bj&ouml;rk

Lars Olof G&ouml;ran Pettersson

Pous S&oslash;rensen

Dorthe Da Gra&ccedil;a Thrige

Gunnar Olsson

Sten Ohlson

Siamak Shoravi

The present invention relates to a novel heterocyclic compound, a pharmaceutical composition comprisining said compound, a method and use of said compound for clinical treatment of medical conditions which may benefit from immunomodulation, e.g. rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis. More particularly the present invention relates to novel heterocyclic compounds, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28. A method of screening compounds for their ability of inhibiting ligand-induced co-stimulatory receptor internalization pathways in immune competent human cells is described. Said immune competent human cells are incubated at conditions capable of inducing co-stimulatory receptor internalization in the presence of at least one test compound and the suppression of the ligand-induced co-stimulatory receptor internalization determined. There is also described a kit for use in such a method, as well as an immunoregulatory drug capable of blocking down-modulation of a ligand-induced receptor.

Immunomodulating compounds

Quinoline derivatives

A chromatographic column for simultaneous purification of several compounds in a sample by dry column chromatography comprised by a plastic tube and containing a sorbent is described, wherein there is an empty volume on top of the sorbent large enough to hold the amount of developing solvent needed to develop the column, wherein the plastic material is transparent or semitransparent to UV and visible light and can be cut with a sharp object, and wherein the sorbent particle size is <40&mgr; and contains a fluorescent material.

Chromatographic method and chromatographic columns therefor

The invention is related to compounds of general formula (I) wherein R is methyl, ethyl, n-propyl, iso-propyl, n-butyl or allyl; R' is methyl, methoxy, fluoro, chloro, bromo, trifluoromethyl, or OCH.sub.x F.sub.y, wherein

The invention is related to compounds of general formula (I) ##STR1## wherein R is Me, Et, n-Pr, iso-Pr, n-Bu, iso-Bu, sec.-Bu or allyl; R' is hydrogen, Me, MeO, fluoro, chloro, brorno, CF.sub.3, or OCH.sub.x F.sub.y ; R' is hydrogen or fluoro, with the proviso that R' is fluoro when R' is fluoro; and further when R' and R' are both hydrogen, R is not Me; R.sub.4 is selected from hydrogen and pharmaceutically acceptable inorganic and organic cations; R.sub.5 is selected from MeS, EtS, n-PrS, iso-PrS, MeSO, EtSO, MeSO.sub.2 and EtSO.sub.2 ; wherein x=0-2, y=1-3 with the proviso that x+y=3; and Me is methyl, Et is ethyl, Pr is propsy and Bu is butyl; and any tautomer, optical isomer and racemate thereof. The invention also relates to pharmaceutical compositions containing a compound of the general formula (I) together with a pharmaceutically acceptable carrier. Included are also processes for the preparation of the compounds of formula (I), as well as methods for the treatment of mammals suffering from diseases resulting from autoimmunity and pathological inflammation by administering of a compound having the formula (I) to said mammal.

The invention relates to compounds of general formula (I) ##STR1## wherein R is selected from ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec.-butyl and allyl; R.sub.4 is selected from hydrogen and pharmaceutically acceptable inorganic and organic cations; R.sub.5 is selected from methyl, ethyl, n-propyl, iso-propyl, methoxy, ethoxy, chloro, bromo, CF.sub.3, and OCH.sub.x F.sub.y ; wherein x=0-2, y=1-3 with the proviso that x+y=3; R.sub.6 is hydrogen; or R.sub.5 and R.sub.6 taken together are methylenedioxy; and any tautomer hereof. The invention also relates to pharmaceutical compositions containing a compound of the general formula (I) together with a pharmaceutically acceptable carrier. Included are also processes for the preparation of the compounds of formula (I), as well as methods of treating mammals suffering from diseases resulting from autoimmunity and pathological inflammation by administering a compound having the formula (I) to said mammal.

Process for separating lipophilic compounds

Piperazinecarboxamides having a phenoxyalkyl or thiophenoxyalkyl side

Growing community of inventors

Lund, Sweden

Tomas Fex